 |
 |
Investor Calendar is powered by PrecisionIR, the leading webcaster of official investor relations events, and offers free access to live and archived corporate communications | |
 |
|
||
|
||||||||
|
|
|
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
June 28, 2012 - 12:00 PM Eastern LHA Life Sciences & Medical Technologies Virtual Conference Press Release More company presentations from 
Seth Lederman, MD Co-Founder, CEO & Chairman Seth Lederman is a physician, scientist, and specialty pharmaceuticals entrepreneur. Prior to founding TONIX, from 2007-2008 Dr. Lederman co-founded and was a managing partner of Konanda Pharma Partners, LLC and Konanda Pharma Fund I, LP. He co-founded and served as director and chairman of its wholly-owned operating companies Validus and Fontus Pharmaceuticals Inc., which market Equetro® (carbamazepine – Extended Release), Marplan® (isocarboxazid) and Rocaltrol® (calcitriol). In 2000 Dr. Lederman founded Targent Pharmaceuticals to develop late-stage oncology drugs including pure-isomer levofolinic acid, which was sold to Spectrum Pharmaceuticals and is now FDA-approved and marketed as Fusilev® for colorectal cancer. In 1998 Dr. Lederman co-founded Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including VLD-cyclobenzaprine. A member of the faculty of Columbia University's College of Physicians and Surgeons since 1985, Dr. Lederman maintains an appointment as Associate Professor. At Columbia, he was an NIH Physician-Scientist from 1985-1990. Dr. Lederman became an Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, he directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman has authored numerous scientific articles, and has been issued several patents for drug development technologies. Dr. Lederman's fundamental research on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen-IDEC and CellTech/UCB. The successful defense of his CD154 patents established important precedents defining the relationship between therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. Dr. Lederman's earlier research efforts in HIV contributed to understanding how the V3 loop of HIV gp120 affected fusion with CD4 cell membranes, an early and essential event in viral entry and infection. Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University's College of Physicians and Surgeons in 1983. He trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital, serving as an attending physician in its Edward Daniels Arthritis and Autoimmunity Clinic from 1988-1996. | |||||||||||||||||||||||||||||||||||||||||||||||||||
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Information contained in this webcast is current as of the date and time first presented. The use of pop-up blocking or firewall software may prevent you from accessing this webcast. Please temporarily disable any of these products you may have while attempting to access this event. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Comments or questions? Click Here Privacy Statement Terms and Conditions ©2000-2013 PrecisionIR. All rights reserved. | |
A part of PrecisionIR Group, www.PrecisionIR.com |
